The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.

By R. Arbeit, D. Maki, F. Tally, Edward Campanaro, B. Eisenstein. Clinical Infectious Diseases, 2004

668 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary. (2011, background): “without a more aggressive dosing strategy [50, 136, 138, 313, 314].”
Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America. (2014, background): “Erysipelothrix rhusiopathiae is resistant to vancomycin, teicoplanin, and daptomycin [133, 134, 172, 173].”
2012 infectious diseases society of america clinical practice guideline for the diagnosis and treatment of diabetic foot infections. (2013, neutral): “Diabetic foot care teams can include (or should have ready access to) specialists in various fields; patients with a DFI may especially benefit from consultation with an infectious disease or clinical microbiology specialist and a surgeon with experience and interest in managing DFIs (strong, low).”
Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. (2014, background): “Erysipelothrix rhusiopathiae is resistant to vancomycin, teicoplanin, and daptomycin [133, 134, 172, 173].”
Antibiotic resistance in Staphylococcus aureus. Current status and future prospects (2017, background): “Daptomycin is now a mainstay of anti-MRSA therapy (Arbeit et al. 2004).”